|Bid||59.40 x 1100|
|Ask||60.35 x 1300|
|Day's Range||59.51 - 60.49|
|52 Week Range||46.48 - 61.34|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||39.70|
|Forward Dividend & Yield||1.40 (2.39%)|
|Ex-Dividend Date||Aug 12, 2021|
|1y Target Est||N/A|
WILMINGTON, Del., October 15, 2021--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. This novel dose and schedule
WILMINGTON, Del., October 08, 2021--Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).
WILMINGTON, Del., October 05, 2021--AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic COVID-19.